Associate Clinical Professor of Medicine, Northwestern University
Oncology
Dr. Bruce E. Brockstein, MD
|
|
Give Review
Bruce Brockstein works in the field of Oncology. He researched medicine at University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine is ranked 10 in research and 19 in primary care medicine He received 6 awards: "America's Top Doctors", "Chicago Magazine: Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Super Doctor" and "Top MD". Bruce Brockstein is also a published MD. He has 59 publication published. The most recent publication is: Oral 5-FU alternatives for the treatment of head and neck cancer. Bruce Brockstein accepts Medicare payments and is listed with Medicare.gov.
Publications
- Promotion of self-management for post treatment cancer survivors: evaluation of a risk-adapted visit.
- Outpatient advance care planning for patients with metastatic cancer: a pilot quality improvement initiative.
- Bilateral areolar leiomyomas in a patient undergoing BRAF inhibition therapy for melanoma.
- Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
- Topical Polyethylene Glycol as a Novel Chemopreventive Agent for Oral Cancer via Targeting of Epidermal Growth Factor Response.
- Outcomes of computerized physician order entry in an electronic health record after implementation in an outpatient oncology setting.
- Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia.
- Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
- Metastatic osteosarcoma: a curable advanced malignancy.
- Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
- Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy.
- Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
- Is patient travel distance associated with survival on phase II clinical trials in oncology?
- Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin ...
- Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanc...
- Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
- Head and neck cancer in 2010: Maximizing survival and minimizing toxicity.
- Management of recurrent head and neck cancer: recent progress and future directions.
- Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radi...
- Oncogenic osteomalacia as a harbinger of recurrent osteosarcoma.
- High-dose chemotherapy with autologous stem cell rescue for breast cancer: yesterday, today and tomorrow.
- Tumor cell contamination of bone marrow harvest products: clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy.
- Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
- Oral 5-FU alternatives for the treatment of head and neck cancer.
- Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
- Oral chemotherapy in head and neck cancer.
- Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors.
- Reduction of distant metastases in head and neck cancer with concomitant chemotherapy.
- Benefits of chemotherapy in head and neck cancer.
- NCCN Practice Guidelines for Head and Neck Cancers.
- Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
- The spectrum of vascular lesions in the mammary skin, including angiosarcoma, after breast conservation treatment for breast cancer.
- Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer.
- Integration of taxanes into primary chemotherapy for squamous cell carcinoma of the head and neck: promise fulfilled?
- A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor supp...
- Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer.
- Swallowing function in patients with head and neck cancer prior to treatment.
- Workshop report: organ preservation strategies in advanced head and neck cancer--current status and future directions.
- Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head ...
- Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor...
- Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient,...
- Blood supply to the spinal cord: anatomic and physiologic correlations.
- The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
- Review: coagulopathy and factor inhibitors.
- Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
- Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
- Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.
- Radiotherapy: Accelerated radiotherapy for HNSCC in developing countries.
- Effect of an electronic health record on the culture of an outpatient medical oncology practice in a four-hospital integrated health care system: 5-year experience.
- Concurrent chemoradiotherapy for head and neck cancer.
- Overview of head and neck cancer.
- Organ preservation for advanced head and neck cancer concomitant chemoradiation.
- Management of sarcomas of the head and neck.
- Radiation-induced leiomyosarcoma: does antimetabolite chemotherapy contribute? A report of three cases.
- Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation.
- High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter pha...
- A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores.
- Head and neck cancers.
Schools
University Of ChicagoThe Pritzker School Of Medicine
University Of Pennsylvania
University Of Pennsylvania Hospital
University Of Chicago Hospitals
University Of IllinoisUrbana
Procedures Preformed
- Cancer Pain Management
- Thoracentesis
Doctors Specialties
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Chicago Magazine: Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
- Top MD
Education
-
University of Chicago -
University of Pennsylvania Health System -
University of Chicago Pritzker School of Medicine
Hospital
-
NorthShore University Health System -
NorthShore Skokie Hospital
Drug Facts
| NPI NUMBER | 1740349695 | |
| NPPES Provider LastName | BROCKSTEIN | |
| NPPES Provider FirstName | BRUCE | |
| NPPES Provider ZIPCode | 602011718 | |
| NPPES Provider State | IL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 513.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 72.0 | |
| Percent Opioid Claims | 14.04 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1740349695 |
| Last Name Of The Provider | BROCKSTEIN |
| First Name Of The Provider | BRUCE |
| View All |
Similar Doctors
|
Dr. Keith I. Block, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Janardan D. Khandekar, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Sara E. Barnato, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Teresa A. Murray Law, MD
This Doctor is OpenDoctor Recommended.
|